Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Date:1/4/2008

SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc. announced today that Matthew J. Meyer has been named General Counsel, a newly established position, and Vice President of Business Development and Licensing. Mr. Meyer is a global life sciences executive and corporate attorney with broad experience with large pharmaceutical, medical device and early-stage companies in the US and Europe. In the business development role, he replaces Timothy J. McBride, who will be furthering his career in Europe. Mr. Meyer will report to Paul Sekhri, President and CEO, and will be responsible for managing the Company's efforts to identify and secure new strategic business opportunities and product acquisitions.

Mr. Meyer brings considerable experience to his new role in the areas of commercial law, business development, marketing and licensing. Before joining Cerimon, Mr. Meyer held senior management positions at Draeger Medical Systems, a global medical device company, most recently serving as Vice President and General Counsel. Prior to Draeger, Mr. Meyer held several positions of increasing responsibility at Novartis Pharma AG in Basel, Switzerland, including serving as Head of Global Marketing Channel Innovations. While at Novartis, he also coordinated and implemented strategic commercial, marketing, research and development initiatives for the Arthritis, Bone, GI and Urology (ABGU) marketing franchise. Previously, Mr. Meyer spent four years as Vice President, Global Business Development and Legal Affairs at Allscripts LLC and five years as a commercial attorney at Pfizer Inc. in New York.

Mr. Meyer graduated Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Cornell University. He earned his Juris Doctor degree from Villanova University School of Law.

"Matt Meyer's proven track record as an incisive leader in business development in the life sciences sector will be a valuable asset to this Company," comment
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... MATEO, Calif., Nov. 24 ...cal company focused on developing and commercializ...ay that Anthony DiTonno, President and Chief Execu...Annual Piper Jaffray Health Care Conference, to be...tel in New York, New York. ,, Mr. DiTonno and ...
(Date:11/24/2009)....24/PRNewswire/--BlueMarbleEnergyCorp.announcedtod...rity(OPDA)wererecentlyawarded$2millionbyWashington...naprivate/publicpartnershiptoconstructthestate,sfi...WA. ,, "Thisinvestmentwillsignificantlyspeedthe...toLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgilv...
(Date:11/24/2009)...rimary efficacy endpoint has been met for patients...cancer, , QUEBEC CITY, Nov. 24 /PRNewswire-Fi...TSX: AEZ) (the "Company"), a global biopharmaceuti...ogy, today announced positive efficacy data from a... conjugate, AEZS-108 (formerly AN-152), in patient...
(Date:11/24/2009)...BLIN, November 24 Shire ...lty biopharmaceutical company, today,announced tha... Agency for,velaglucerase alfa, the company,s enzy...tment of Type 1 Gaucher disease. This is the third... has been submitted, with previous,submissions in ...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...pace, the world,s leading,online bioscience job bo...,announced today an alliance with IBC Life Science...eer Fair in conjunction with IBC,s Drug Discovery,...gress (DDT) in Boston,during August of 2008., The...0 life science,professionals from the BioSpace com...
... & high-tech market will grow to over $2 bi...oup, WALTHAM, Mass., April 17 According to Mille...n and High-Tech Devices 2008,and European Markets ...ts,the visualization device market in these region... 2007. This market will see rapid growth, driven b...
...tees Will Solve and Prevent Crimes, CARLSBAD, N.M...joined together in praising the efforts of US Atto... rule that will finally allow,implementation of fo...in,late 2005. These families have each been active...es. The federal law requires a DNA sample from any...
Other Biology Technology:BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress 2BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress 3High-Definition Technology to Revolutionize US & European Visualization Device Markets 2Mothers of Victims Applaud Federal Effort to Collect DNA Upon Arrest 2
(Date:11/23/2009).... November 23, 2009 Applied mathematicians disse...ancifolia ), a characteristic long leaf with a sad... along the edges. The simple cause of the lily,s f...ding during differential growthwas revealed by usi...bbons. , Haiyi Liang, a postdoctoral student at ...
(Date:11/23/2009)...e Wildlife Conservation Society says that western ...public of Congopart of the "mother lode" of more t...ing increasingly threatened by growing humans acti...ction of the swamp forests adjacent to the southwe... surveys confirmed that high densities of the grea...
(Date:11/23/2009)...rent research suggests that a common oral bacteriu...report by Nichols et al, "Unique Lipids from a Com...Ligands Capable of Enhancing Autoimmunity," appear...nal of Pathology . , Multiple sclerosis (MS), a ...and spinal cord, affects nearly 1 in 700 people in...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Factors from common human bacteria may trigger multiple sclerosis 2Arcadia Resources Announces Closing of 2411 1 Million Financing 61915 1Arcadia Resources Announces Closing of 2411 1 Million Financing 61915 2Inimex Announces Appointment of New CEO 14941 1Inimex Announces Appointment of New CEO 14941 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2
...le ways and, because of this, restoration ecologis...searchers, in a recent article published in Restor...he past may not always be applicable in the future...is restoring environments undergoing the most rapi...bal climate change is likely to have important reg...
...ike creating a topiary garden. Shrubs don,t automa...and neither do immature nerve cells immediately re... either vegetal or neuronal, must first sprout and...rons extend fibers called axons to target cells in...ells while others shoot past their target cells. A...
...HIV-1--the virus predominantly responsible for hum... new evidence reveals. A gene function lost during...o spur the fatal immune system failures that are t...ne 16, 2006 Cell. , AIDS has killed more than 25 m...1, according to The Joint United Nations Programme...
Other Biology News:Salk and Stanford teams join forces to reveal two paths of neurodegeneration 2Salk and Stanford teams join forces to reveal two paths of neurodegeneration 3HIV-1's high virulence might be an accident of evolution 2HIV-1's high virulence might be an accident of evolution 3HIV-1's high virulence might be an accident of evolution 4
PlateCrane EX from Hudson Control Group, Inc.
4% Agarose Gel from Invitrogen
BD BaculoGold Max-XP Insect Cell Medium from BD Biosciences Pharmingen
GIBCO Newborn Calf Serum; Heat-Inactivated from Invitrogen
Biology Products: